Announcements Trials
Browse Landscape

Phase

Phase 2 24Phase 3 5Phase 1/2 4Phase NA 3Phase 4 3Phase 2/3 1

Status

Completed 14Recruiting 13Active not recruiting 6Unknown 5Not yet recruiting 4Terminated 3Withdrawn 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 3Breast 1

Conditions

Liver Neoplasms 1Esophageal Squamous Cell Carcinoma 1Breast Neoplasms 1Advanced Hepatocellular Carcinoma (HCC) 1

Interventions

Bevacizumab 14Injections 13Drug Therapy 10Gemcitabine 9toripalimab 8venetoclax 7Specimen Handling 7Magnetic Resonance Spectroscopy 7Cyclophosphamide 7Carboplatin 7pembrolizumab 6irinotecan sucrosofate 6Temozolomide 6HMPL-013 6tislelizumab 5sintilimab 5fludarabine 5N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 5Fluorouracil 5Etoposide 5Cisplatin 5Biopsy 5osimertinib 4lenvatinib 4Rituximab 4Radiotherapy 4Pemetrexed 4Paclitaxel 4Oxaliplatin 4Leucovorin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × Not yet recruiting × lenvatinib × Clear all
NCT07282509 2025-12-15

Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of Advanced Liver Cancer

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 1/2 Not yet recruiting
116 enrolled
Gastrointestinal

Advanced Hepatocellular Carcinoma (HCC)

NCT06746961 2024-12-24

Efficacy and Safety of QL1706 Plus Lenvatinib As 2nd Line Theapy in Patients with Metastatic Esophageal Carcinoma After Disease Progression on ICIs Therapy

The First Affiliated Hospital of Zhengzhou University

Phase 1/2 Not yet recruiting
49 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT06409637 2024-05-10

FOLFOX Plus Lenvatinib Adjuvant Therapy for Hepatocellular Carcinoma Post-Liver Transplantation

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 1/2 Not yet recruiting
62 enrolled
Gastrointestinal

Liver Neoplasms

NCT06140576 2023-11-20

The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial.

Zhejiang Cancer Hospital

Phase 1/2 Not yet recruiting
58 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡